导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.83% | 4049/4773 |
| 近一周 | -1.62% | 593/5462 |
| 近一月 | -1.68% | 999/5421 |
| 近一季 | -9.49% | 3229/5209 |
| 近半年 | -18.77% | 4296/4920 |
| 近一年 | -2.10% | 2971/4366 |
| 近两年 | 32.45% | 2181/2954 |
| 近三年 | -3.30% | 1975/2253 |
| 成立以来 | 44.56% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.34% 2244/4961 |
-1.51% 3353/5312 |
- - |
- - |
| 2025 | 23.78% 1843/4813 |
-1.13% 2586/3635 |
10.31% 254/4076 |
6.81% 3506/4524 |
6.25% 368/4813 |
| 2024 | 0.41% 2074/3463 |
-12.67% 2462/2808 |
1.44% 471/3014 |
12.34% 2370/3129 |
0.89% 1153/3463 |
| 2023 | -21.81% 1910/2656 |
-7.87% 2177/2280 |
0.62% 298/2385 |
-9.40% 1811/2515 |
-6.90% 1972/2655 |
| 2022 | -25.28% 1305/2207 |
-24.45% 1765/1919 |
8.87% 320/2016 |
-6.13% 94/2113 |
-3.23% 1843/2208 |
| 2021 | 19.08% 198/1822 |
-21.30% 1211/1255 |
12.70% 318/1330 |
10.56% 119/1466 |
21.44% 22/1822 |
| 2020 | 89.79% 24/1250 |
0.12% 172/1028 |
14.24% 561/1067 |
32.68% 6/1164 |
25.06% 28/1184 |
| 2019 | 23.37% 629/1092 |
30.65% 237/754 |
-9.39% 650/804 |
5.57% 143/850 |
-1.28% 900/918 |
| 2018 | -27.48% 423/834 |
- - |
- - |
- - |
-15.47% 606/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 鹏华空天军工指数(LOF)A VS. 长安沪深300非周期A(740101) |